Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework

To the Editor In a recent study, Ben-Aharon et al¹ showed that only 3 of 10 indications of immune checkpoint inhibitors qualified for tail-of-the-curve bonus points of the American Society of Clinical Oncology Value Framework (ASCO-VF).² We were puzzled by these counterintuitive findings in light of previous studies using the ASCO-VF and of our experience.³ The authors called for lowering the bar so that more trials could reach thresholds.